Search

Your search keyword '"Mesia C"' showing total 103 results
Start Over Author "Mesia C"
103 results on '"Mesia C"'

1. P1.01-01 Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER)

Author

Jové, M., primary, Gausachs, M., additional, Bosch-Barrera, J., additional, Carcereny, E., additional, Teule, A., additional, Mosteiro, M., additional, Pineda, M., additional, Tornero, E., additional, Palmero, R., additional, Vilarino, N., additional, Ruffinelli, J.C., additional, Mesia, C., additional, Saldaña, J., additional, Cuellar, A., additional, Brenes, J., additional, Hernandez, A., additional, Fina, C., additional, Brunet, J., additional, Domenech, M., additional, Moran, T., additional, Sais, E., additional, Lazaro, C., additional, and Nadal, E., additional

Published
2023
Full Text
View/download PDF

2. Exploring the management of elderly patients with glioblastoma using data from GEINO14-01 and EX-TEM

Author

Gately, L., primary, Mesia, C., additional, Sepulveda, J.M., additional, Del Barco, S., additional, Pineda, E., additional, Girones, R., additional, Fuster, J., additional, Hong, W., additional, Gill, S., additional, Navarro, M., additional, Herrero, A., additional, Dowling, A., additional, De Las Penas, R., additional, Vaz, M.A., additional, Alonso, M., additional, Lwin, Z., additional, Harrup, R., additional, Peralta, S., additional, Gibbs, P., additional, and Balana, C., additional

Published
2023
Full Text
View/download PDF

3. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients

Author

Balaña, C., Estival, A., Teruel, I., Hardy-Werbin, M., Sepulveda, J., Pineda, E., Martinez-García, M., Gallego, O., Luque, R., Gil-Gil, M., Mesia, C., Del Barco, S., Herrero, A., Berrocal, A., Perez-Segura, P., De las Penas, R., Marruecos, J., Fuentes, R., Reynes, G., Velarde, J. M., Cardona, A., Verger, E., Panciroli, C., and Villà, S.

Published
2018
Full Text
View/download PDF

6. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01)

Author

Balana C, Vaz M, Sepulveda J, Mesia C, Del Barco S, Pineda E, Munoz-Langa J, Estival A, de Las Penas R, Fuster J, Girones R, Navarro L, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-Garcia M, Berrocal A, Gallego O, Luque R, Perez-Martin F, Esteve A, Munne N, Domenech M, Villa S, Sanz C, and Carrato C

Subjects
MGMT methylation, extended adjuvant temozolomide, glioblastoma, prognosis
Abstract

BACKGROUND: Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for six cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate. We performed a phase II randomized, trial investigating whether extending adjuvant temozolomide for more than six cycles improved outcome.; METHODS: Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after six cycles of adjuvant temozolomide were centrally randomized to stop (control arm) or continue (experimental arm) temozolomide up to a total of twelve cycles at the same doses they were receiving in cycle 6. Patients were stratified by MGMT methylation and measurable disease. The primary endpoint was differences in 6-month progression-free survival (PFS). Secondary endpoints were PFS, overall survival (OS) and safety. (Clinicaltrials.gov NCT02209948).; RESULTS: From August 2014 to November 2018, 166 patients were screened, seven of whom were ineligible. Seventy-nine patients were included in the stop arm and 80 in the experimental arm. All patients were included in the analyses of outcomes and of safety. There were no differences in 6-month PFS (control 55.7%; experimental 61.3%), PFS, or OS between arms. MGMT methylation and absence of measurable disease were independent factors of better outcome. Patients in the experimental arm had more lymphopenia (P < 0.001), thrombocytopenia (P < 0.001), and nausea and vomiting (P = 0.001).; CONCLUSIONS: Continuing temozolomide after six adjuvant cycles is associated with greater toxicity but confers no additional benefit in 6-month PFS. © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Published
2020

8. Somatic Genome Alterations in Lung Cancer Patients Diagnosed with Li Fraumeni Syndrome

Author

Jove, M, Moran, T, Teule, A, Menendez, M, Gausachs, M, Vilarino, N, Sanchez, RP, Cirauqui, B, Estival, A, Carcereny, E, Domenech, M, Navarro, M, Bosch-Barrera, J, Fina, C, Izquierdo, A, Ruffinelli, JC, Varela, M, Mesia, C, Hernandez, A, Gonzalez, S, Lazaro, C, Brunet, J, and Nadal, E

Subjects
EGFR mutant lung cancer, Lung cancer, Li Fraumeni Syndrome
Published
2019

11. Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial

Author

Salgado, M.A.V., primary, Sepulveda Sanchez, J.M., additional, del barco, S., additional, Pineda, E., additional, Fuster, J., additional, Navarro Martin, M., additional, Herrero Ibañez, A., additional, Alonso, M., additional, Perez, J., additional, Mesia, C., additional, Munoz-Langa, J., additional, de las Penas Bataller, R., additional, Peralta, S., additional, Olier, C., additional, Pérez-Segura, P., additional, Estival, A., additional, Carrato, C., additional, Saez, C., additional, Gil, M.J., additional, and Balana, C., additional

Published
2019
Full Text
View/download PDF

12. P1.01-54 Somatic Genome Alterations in Lung Cancer Patients Diagnosed with Li Fraumeni Syndrome

Author

Jove, M., primary, Moran, T., additional, Teule, A., additional, Menendez, M., additional, Gausachs, M., additional, Vilariño, N., additional, Sánchez, R. Palmero, additional, Cirauqui, B., additional, Estival, A., additional, Carcereny, E., additional, Domenech, M., additional, Navarro, M., additional, Bosch-Barrera, J., additional, Fina, C., additional, Izquierdo, A., additional, Ruffinelli, J.C., additional, Varela, M., additional, Mesia, C., additional, Hernandez, A., additional, Gonzalez, S., additional, Lazaro, C., additional, Brunet, J., additional, and Nadal, E., additional

Published
2019
Full Text
View/download PDF

13. P14.58 Extending adjuvant temozolomide longer than six cycles doesn’t add any benefit to glioblastoma patients according to the randomized GEINO-014 TRIAL

Author

Balana, C, primary, Sepulveda, J, additional, Pineda, E, additional, Vaz, M, additional, Mesia, C, additional, Fuster, J, additional, Girones, R, additional, Muñoz-Langa, J, additional, Navarro, M, additional, Alonso, M, additional, Gil Gil, M, additional, Herrero, A, additional, Estival, A, additional, Gallego, O, additional, Peralta, S, additional, Olier, C, additional, Pérez-Segura, P, additional, Covela, M, additional, Martinez García, M, additional, Domenech, M, additional, Carrato, C, additional, Sanz, C, additional, Velarde, J, additional, Berrocal, A, additional, Luque, R, additional, De las Peñas, R, additional, and Del Barco, S, additional

Published
2019
Full Text
View/download PDF

18. P2.08-006 Immunological Biomarkers Characterization in Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemo-Radiotherapy

Author

Saigi, M., primary, Baixeras, N., additional, Rullan, A., additional, Sirvén, M. Bergamino, additional, Navarro-Martin, A., additional, Arnaiz, M., additional, Ruffinelli, J.C., additional, Mesia, C., additional, Palmero, R., additional, Padrones, S., additional, Cardenal, F., additional, Sanchez-Cespedes, M., additional, and Nadal, E., additional

Published
2017
Full Text
View/download PDF

19. Treatment of recurrent glioblastoma (GB) after radiotherapy (RT) and temozolomide (TMZ): A retrospective analysis of the GLIOCAT study

Author

Gil-Gil, M., primary, Velarde, J.M., additional, Martinez-Garcia, M., additional, Gallego, O., additional, del Barco, S., additional, Pineda, E., additional, Mesia, C., additional, Estival, A., additional, Vilariño, N., additional, Marruecos, J., additional, Verger, E., additional, Craven, J., additional, Fuentes, R., additional, Lucas, A., additional, Macià, M., additional, Carrato, C., additional, Vidal, N., additional, Velasco, R., additional, Villa, S., additional, and Balana, C., additional

Published
2017
Full Text
View/download PDF

20. Galectin-1 (Gal-1) expression as a prognostic factor in a homogenous cohort of glioblastoma (GB) (Gliocat study)

Author

Vilariño Quintela, N., primary, Martinez Bosch, N., additional, Balana, C., additional, Alameda, F., additional, Estival, A., additional, Pineda, E., additional, Del Barco, S., additional, Gil-Gil, M., additional, Mesia, C., additional, Gallego, O., additional, Carrato, C., additional, Ribalta, T., additional, Vidal, N., additional, Dela Iglesia, N., additional, Arpi, O., additional, Capellades, J., additional, Garcia, N., additional, Velarde, J.M., additional, Navarro, P., additional, and Martinez-Garcia, M., additional

Published
2017
Full Text
View/download PDF

29. 347P - Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study

Author

Pineda, E., Martinez-Garcia, M., Estival, A., Gil-Gil, M., Del Barco, S., Gallego, O., Verger, E., Marruecos, J., Fuentes, R., de Grigno, J. Craven-BartleLamote, Mesía, C., García, N., Alameda, F., Velarde, J.M., Pujol, T., Oleaga, L., Carrato, C., Capellades, J., Villà, S., and Balana, C.

Published
2016
Full Text
View/download PDF

31. 338P - MGMT methylated (Met) patients (p) with glioblastoma (GBM) have a better prognosis with an earlier response (ER) than those who have a late response or pseudoprogression (LR/PsP). Results of the Gliocat study

Author

Estival, A., Pineda, E., Martinez-Garcia, M., Marruecos, J., Mesía, C., Lucas, A., Macia, M., Gil, M., Gallego, O., Verger, E., Del Barco, S., Fuentes, R., Craven, J., García, N., Villà, S., Velarde, J.M., Carrato, C., Ribalta, T., Arpi, O., and Balana, C.

Published
2016
Full Text
View/download PDF

32. Coronary steal syndrome after coronary artery bypass for anomalous aortic origin of a coronary artery.

Author

Youdelman, Benjamin A, Pelletier, Glenn J, Mesia, C Igor, Jacobs, Marshall L, Youdelman, Benjamin A, Pelletier, Glenn J, Mesia, C Igor, and Jacobs, Marshall L

Abstract

Anomalous aortic origin of a coronary artery found in a symptomatic 9-year-old boy was initially treated with coronary artery bypass grafting using a left internal mammary artery anastomoses to the left anterior descending coronary artery, but resulted in coronary ischemia, likely from a steal phenomenon. Subsequent transection of the proximal left internal mammary artery with anastomosis to the ascending aorta, and coronary ostial enlargement, resulted in a durable treatment. We recommend caution in choosing coronary artery bypass grafting using a left internal mammary artery pedicle graft for the treatment of anomalous aortic origin of a coronary artery.

Published
2009

33. Coronary steal syndrome after coronary artery bypass for anomalous aortic

Author

Youdelman, Benjamin A, Pelletier, Glenn J, Mesia, C. Igor, Jacobs, Marshall L, Youdelman, Benjamin A, Pelletier, Glenn J, Mesia, C. Igor, and Jacobs, Marshall L

Abstract

Anomalous aortic origin of a coronary artery (AAOCA) found in a symptomatic 9 year old boy was initially treated with coronary artery bypass (CABG) using a left internal mammary artery (LIMA) anastomoses to the left anterior descending coronary artery (LAD) but resulted in coronary ischemia, likely from a steal phenomenon. Subsequent transection of the proximal LIMA with anastomosis to the ascending aorta, and coronary ostial enlargement, resulted in a durable treatment. We recommend caution in choosing CABG using a LIMA pedicle graft for the treatment of AAOCA.

Published
2008

34. P3-14-27: Pegylated Liposomal Doxorubicin (PLD) as Primary Treatment in Estrogen Receptor (ER) and HER2 Poor Breast Cancer and Risk of Developing Cardiotoxicity or Elderly Patients (pt). Results from the Phase II CAPRICE Study.

Author

Gil, MJ, primary, Bellet, C, additional, Llombart, A, additional, Ojeda, B, additional, Manso, L, additional, Mesia, C, additional, Morales, S, additional, García-Martinez, H, additional, Martínez, N, additional, Melé, M, additional, Fernández-Ortega, A, additional, and Baselga, J, additional

Published
2011
Full Text
View/download PDF

36. 6500 ORAL Randomized phase II trial using concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) for unresectable stage III non-small cell lung cancer (NSCLC) patients (pts). Mature results of the SLCG 0008 study

Author

Garrido, P., primary, Massuti, B., additional, Jimenez, A., additional, Samper, P., additional, Mesia, C., additional, Rodriguez, N., additional, Lianes, P., additional, Arellano, A., additional, Ramos, A., additional, and Rosell, R., additional

Published
2007
Full Text
View/download PDF

41. Transcatheter Angioplasty for Acquired Pulmonary Vein Stenosis After Radiofrequency Ablation

Author

Qureshi, Athar M., primary, Prieto, Lourdes R., additional, Latson, Larry A., additional, Lane, Geoffrey K., additional, Mesia, C. Igor, additional, Radvansky, Penelope, additional, White, Richard D., additional, Marrouche, Nassir F., additional, Saad, Eduardo B., additional, Bash, Dianna L., additional, Natale, Andrea, additional, and Rhodes, John F., additional

Published
2003
Full Text
View/download PDF

44. Selective timing for the arterial switch operation.

Author

Duncan, Brian W., Poirier, Nancy C., Mee, Roger B. B., Drummond-Webb, Jonathan J., Qureshi, Athar, Mesia, C. Igor, Graney, June A., Malek, Cheryl L., and Latson, Larry A.

Subjects
ARTERIAL surgery, INFANTS, MORTALITY, HOSPITAL care
Abstract

: BackgroundTo determine outcomes for the arterial switch operation individualized according to the underlying anatomy and clinical status.: MethodsA retrospective review of a consecutive series of infants less than 90 days of age who underwent the arterial switch operation at a single institution.: ResultsFrom July 1993–April 2001, 117 infants underwent an arterial switch operation before 90 days of age. Seventy-five patients (64%) had transposition of the great arteries with intact ventricular septum with the aim of operation before 14 days of age; however, 8 of these patients had delayed presentation (range 15–46 days). Thirty-five patients (30%) had transposition with a ventricular septal defect (30 patients) or double outlet right ventricle (5 patients) and normal arch anatomy and were repaired within the first 90 days of life depending on the severity of heart failure at a median of 12 days of age (range 3–83 days). Seven patients (6%) had associated aortic coarctation (5 patients) or interrupted aortic arch (2 patients). One patient died during hospitalization (0.85% hospital mortality) and one patient died from noncardiac causes during a median follow-up of 35 months (1.7% total mortality). Four patients required intervention during follow-up (3.4%) for new aortic coarctation (2 patients), supravalvar pulmonic stenosis (1 patient), or right hemi-diaphragm paralysis (1 patient).: ConclusionsIndividualized timing for the arterial switch operation within the first ninety days of life produces excellent survival rates for all types of transposition physiology with the expectation of a satisfactory course during follow-up. [Copyright &y& Elsevier]

Published
2004
Full Text
View/download PDF

48. Results of the double switch operation for congenitally corrected transposition of the great arteries

Author

Duncan, Brian W., Mee, Roger B.B., Mesia, C. Igor, Qureshi, Athar, Rosenthal, Geoffrey L., Seshadri, Shivaprakash G., Lane, Geoffrey K., and Latson, Larry A.

Subjects
*CHROMOSOMAL translocation, *PULMONARY artery
Abstract

Objective: To determine the outcomes for a program that utilizes the double switch operation as the primary approach for congenitally corrected transposition. Methods: The records of 46 consecutive patients from a single institution who had undergone a double switch operation from October 1993 to March 2002 were reviewed. The records of 24 patients who were evaluated during the same period and felt not to be candidates for the double switch operation or who are awaiting double switch after pulmonary artery banding were also reviewed. Results: The median age at operation was 28 months (range 2 months to 16.3 years). Associated defects included ventricular septal defect 40, pulmonic stenosis 13 and pulmonary atresia 16. Twenty-six patients underwent an arterial switch operation combined with a Senning procedure while 20 patients underwent combined Rastelli and Senning procedures. Before the double switch, 12 patients had required pulmonary artery banding and 21 patients had systemic to pulmonary artery shunts. The median duration of stay in the intensive care unit was 3.5 days (range 2–60 days) and the median duration of total hospital stay was 8 days (range 5–60 days). There were no hospital deaths; one patient died 5 months after discharge due to an arrhythmogenic cardiac arrest during a median follow-up of 24 months [long-term survival 98% (95% CI 89–100%)]. Conclusions: The double switch operation may be performed with excellent hospital and long-term survival. The theoretical advantages of this procedure which enables the morphologic left ventricle and mitral valve to support a systemic pressure load must be established by careful follow-up of these patients. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

49. Creation of a dual-coronary system for anomalous origin of the left coronary artery from the pulmonary artery utilizing the trapdoor flap method

Author

Ando, Makoto, Mee, Roger B.B., Duncan, Brian W., Drummond-Webb, Jonathan J., Seshadri, Shivaprakash G., and Igor Mesia, C.

Subjects
*PULMONARY artery, *CORONARY artery bypass
Abstract

Objective: Results of the repair of anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) have improved. Direct implantation of the anomalous coronary artery into the ascending aorta establishes a dual-coronary system and is the goal of current surgical approaches. We report the development of our surgical technique for ALCAPA. Methods: Between September 1993 and December 2000, 13 patients underwent surgery for ALCAPA. There were four males and nine females. Ages ranged from 1 month to 25 years (median=3.9) and weight ranged from 2.6 to 102 kg (median=16.8). One patient had previously undergone an operative procedure at an outside institution. Results: Direct implantation of the anomalous coronary artery into the ascending aorta was feasible in 12 of 13 patients. In situ transfer was performed in one patient with an intramural coronary artery. The first case in the series required an intrapulmonary baffle reconstruction (Takeuchi procedure) because the coronary artery arose remotely from the ascending aorta from the left-anterior sinus of the PA. For coronary transfer, a trapdoor flap was created on the ascending aorta for the implantation of the coronary button and the sinus defect in the main PA was augmented with a pericardial patch. The left ventricular (LV) shortening fraction was improved from a median value of 27% (range 12–36%) preoperatively to 33% (range 24–45%) in the immediate postoperative period (P=0.004). The LV end-diastolic dimension decreased from a median value of 36 mm (range 22–70 mm) preoperatively to 29 mm (range 19–56 mm) in the immediate postoperative period (P=0.004). There has been no mortality or reoperation during a median follow-up of 36 months. Conclusions: Using a standard technique, direct implantation of the anomalous coronary artery into the ascending aorta was achieved in all cases but one. At intermediate follow-up, LV function had improved by echocardiography. No postoperative mechanical circulatory support was required in any of these patients. This operative technique is reproducible and is applicable to the majority of patients with ALCAPA. [Copyright &y& Elsevier]

Published
2002
Full Text
View/download PDF

50. Intracardiac echocardiography during transcatheter interventions for congenital heart disease

Author

Rhodes Jr., John F., Qureshi, Athar M., Preminger, Tamar J., Tuzcu, E. Murat, Casserly, Ivan P., Dauterman, Kent W., Prieto, Lourdes R., Mesia, C. Igor, Lane, Geoffrey K., Radvansky, Penny A., Latson, Larry A., and Rhodes, John F Jr

Subjects
*TRANSESOPHAGEAL echocardiography, *CONGENITAL heart disease, *HEART abnormalities, *CATHETERS
Abstract

Although transesophageal echocardiography is often used for guidance during transcatheter interventions, few data exist regarding the use of the newer modality of intracardiac echocardiography. This brief report summarizes our single center experience using intracardiac echocardiographic guidance during transcatheter interventional procedures for congenital heart disease. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results